Protocol Page


	Study ID (Protocol Number)
	CA212-001


	STUDY LOCATIONS*
	B. Douglas Smith, M.D. Baltimore, MD 21287 Recruiting	Moores Ucsd Cancer Center La Jolla, CA 92037 Recruiting
	Local Institution Boston, MA 02215 Not yet recruiting	The University Of Texas Md Anderson Cancer Center Houston, TX 77030 Recruiting
	*Not all study site locations may be listed - please check back soon for updated information. For more information regarding other participating countries, please visit clinicaltrials.gov.

	STUDY NAME
	First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
	STUDY OVERVIEW
	The purpose of this study is to assess the safety and tolerability of BMS-936564 (MDX-1338) in relapsed Acute myelogenous leukemia (AML) and other selected B-cell cancers and to determine the maximum tolerated dose (MTD) of the drug alone in relapsed/refractory AML

The study information provided here is a portion of what is available on ClinicalTrials.gov. Please visit ClinicalTrials.gov for complete information about this and other clinical studies.